Trial · NCT05857059
Misoprostol for Induction of Labor in Obese Women: Comparison Between 25 and 50 mcg Oral Administration
NCT05857059, Not applicable, Unknown, Unidade Local de Saúde de Coimbra, EPE
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Misoprostol for Induction of Labor in Obese Women: Comparison Between 25 and 50 mcg Oral Administration. Trials, record NCT05857059. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05857059
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Misoprostol for Induction of Labor in Obese Women: Comparison Between 25 and 50 mcg Oral Administration
- NCT number
- NCT05857059
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 228 participants, estimated
- Lead sponsor
- Unidade Local de Saúde de Coimbra, EPE
- Conditions
- Labor, Induced, Obesity, Pregnancy, Cesarean Section
- Interventions
- Misoprostol 25 mcg, Misoprostol 50 mcg
- First posted
- 2023-05-12
- Last updated
- 2023-10-24
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cesarean section rates | Up to 3 days after first misoprostol intake until delivery (vaginal or cesarean section) | Calculation in percentage. An average of 22% cesarean section rate in non-obese pregnant women undergoing IOL was determined, with a between-groups difference of 15% on cesarean section rates being considered clinically significant. |
| Primary | Indication for cesarean section | Delivery | The American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine guidelines for caesarean section indications are used. When a caesarean section is performed, it will be classified in mutually exclusive categories. These are: First stage labor dystocia: Yes/No Second stage labor dystocia: Yes/No Abnormal or indeterminate fetal heart rate tracing: Yes/No Failed induction: Yes/No |
| Secondary | Rate of vaginal delivery within 24 hours | Time of first misoprostol intake until vaginal delivery | Percentage of eutocic or instrumental deliveries that occured within a 24h of the first misoprostol intake |
| Secondary | Time interval from the first dose of misoprostol to vaginal delivery | Time of first misoprostol intake until vaginal delivery | Median time in hours |
| Secondary | Rate of instrumental delivery | Delivery | Percentage of vaginal deliveries that need instrumentation with ventouse or forceps |
| Secondary | Time interval from the first dose of misoprostol to cesarean section delivery | Time of first misoprostol intake until cesarean section delivery | Median time in hours |
| Secondary | Incidence of misoprostol adverse effects | Time of first misoprostol intake until vaginal or cesarean section delivery | Tachysystole (defined as at least six uterine contractions in 10 minutes for two consecutive 10-minute periods) and hyperstimulation (defined as the presence of tachysystole or a prolonged uterine contraction lasting 2 or more minutes associated with fetal heart rate abnormalities) will be evaluated |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05857059
GET https://conductscience.org/api/trials/v1/NCT05857059/registered